{
  "id": 16588939,
  "title": "BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results",
  "url": "https://urgent.news/2026/10/26/biontech-dualitybio-ponder-next-steps-for-her2-adc-after-modest",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T10:34:34.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/biontech-dualitybio-ponder-next-steps-for-her2-adc-after-modest-breast-cancer-results/"
  },
  "original_language": "en",
  "account": null,
  "summary": "BioNTech and DualityBio are mulling what to do next with trastuzumab pamirtecan in certain breast cancer patients after the antibody-drug conjugate delivered a “statistically significant, yet modest” success in a Phase 3 trial. The drugmakers ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}